BCTX

Business Context and Reporting Period

Company: Briacell Therapeutics Corp. (BCTX)
Filing Type: Form 8-K (Current Report)
Reporting Date: April 24, 2025 (Event Date: April 28, 2025)
Context: The Company consummated a public offering of Units and Pre-funded Units to raise capital for working capital requirements, general corporate purposes, and the advancement of business objectives.

Key Financial Metrics

Capital Raised:

• Gross Proceeds (Base Offering): Approximately $12.0 million from the sale of 2,005,967 Units and 660,700 Pre-funded Units.
• Gross Proceeds (Over-Allotment): Approximately $1.8 million from the exercise of the over-allotment option (399,999 common shares and warrants).
• Total Gross Proceeds: Approximately $13.8 million.

Offering Pricing:

• Unit Price: $4.50 per Unit (1 Common Share + 1 Warrant).
• Pre-funded Unit Price: $4.499 per Pre-funded Unit (1 Pre-funded Warrant + 1 Warrant).
• Underwriting Discount: 7.5% (Purchase price to underwriters was $4.1625 per Unit and $4.1615 per Pre-funded Unit).
• Reimbursed Expenses: $182,500 paid to the Representative.

Debt and Liquidity: The filing does not provide specific data on existing debt levels, cash flow, or liquidity ratios prior to this offering.

Material Changes

Capital Structure Changes:

• Equity Issuance: Significant increase in outstanding common shares via the sale of Units and Pre-funded Units.
• Warrant Issuance: Issuance of Warrants (BCTXZ) exercisable at $5.25 per share and Pre-funded Warrants exercisable at $0.001 per share.
• Representative's Warrants: Issuance of 153,333 warrants to the underwriter (ThinkEquity LLC) exercisable at $5.625 per share, expiring April 24, 2030.

Trading Status: Warrants commenced trading on the Nasdaq Capital Market under the symbol "BCTXZ" on April 25, 2025.

Guidance, Outlook, and Risks

Use of Proceeds: Net proceeds are designated for working capital, general corporate purposes, and advancing business objectives. No specific revenue guidance or operational milestones were detailed in this filing.

Lock-Up Provisions:

• Executive Officers: Restricted from selling shares for 60 days from the date of the Underwriting Agreement.
• Directors: Restricted from selling shares for 3 months from the date of the Underwriting Agreement.

Warrant Restrictions: Holders are restricted from exercising warrants if it would result in beneficial ownership exceeding 4.99% (or 9.99% with 61 days' notice) of outstanding common shares.

Investor Verification Checklist

• Net Proceeds Calculation: Verify the final net proceeds after deducting the 7.5% underwriting discount and the $182,500 expense reimbursement.
• Dilution Impact: Assess the immediate dilution from the 2,005,967 Units, 660,700 Pre-funded Units, and 399,999 over-allotment shares.
• Warrant Economics: Review the exercise prices ($5.25 for public warrants, $5.625 for representative warrants) relative to the current market price.
• Pre-funded Warrant Exercise: Confirm the timeline and conditions for the exercise of Pre-funded Warrants at $0.001 per share.
• Lock-Up Expiry: Note the specific dates when executive and director lock-up periods expire to anticipate potential selling pressure.